
Vas Narasimhan
Vas Narasimhan is the Chief Executive Officer of Novartis, a leading global healthcare company. Under his leadership, he has focused on advancing innovative therapies while addressing challenges in healthcare costs and access. Narasimhan advocates for sustainable practices in the pharmaceutical industry, emphasizing the need for ethical pricing of medications to ensure that life-saving treatments are accessible to all patients.
Global Media Ratings
Countries Mentioned
Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
---|---|---|---|---|---|---|---|---|
Australia | 1 | 7.00 | 0.07% | +0% | 25,499,884 | 17,478 | $1,380,000 | 946$ |
Totals | 1 | 25,499,884 | 17,478 | $1,380,000 | 946$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Australia:
Novartis boss Vas Narasimhan said in May that China is very business friendly and stable.
7
Switzerland:
Vas Narasimhan, the CEO of Novartis, called for higher drug prices in Europe alongside Sanofi CEO Paul Hudson.
6
United States:
Novartis, represented by CEO Vas Narasimhan, plans to invest $23 billion in building or expanding drug manufacturing facilities.
8
Switzerland:
Vas Narasimhan, the CEO of Novartis, expressed hope that the EU Commission and the Swiss government would consider how innovation can be valued.
6
Slovenia:
Vas Narasimhan, the CEO of Novartis, argues that current low drug prices in Europe hinder growth and reduce the attractiveness of innovation for the pharmaceutical industry.
6
Croatia:
Vas Narasimhan earned 19.2 million Swiss francs as the CEO of Novartis, surpassing Sergio Ermotti's earnings.
6
Croatia:
Vas Narasimhan earned 19.2 million Swiss francs as the CEO of Novartis.
6
Switzerland:
Vas Narasimhan received a salary package of 19.2 million francs at Novartis.
5
Switzerland:
Vas Narasimhan, the CEO of Novartis, has also faced scrutiny for his high salary.
4
Switzerland:
Vas Narasimhan received a salary package of over 19 million francs, which drew significant criticism.
2